29.40
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$29.80
Aprire:
$29.98
Volume 24 ore:
68,224
Relative Volume:
0.66
Capitalizzazione di mercato:
$414.96M
Reddito:
$138.20M
Utile/perdita netta:
$5.52M
Rapporto P/E:
77.37
EPS:
0.38
Flusso di cassa netto:
$9.86M
1 W Prestazione:
+1.31%
1M Prestazione:
+7.42%
6M Prestazione:
-26.50%
1 anno Prestazione:
-29.93%
Surmodics Inc Stock (SRDX) Company Profile
Nome
Surmodics Inc
Settore
Industria
Telefono
(952) 500-7000
Indirizzo
9924 W 74TH ST, EDEN PRAIRIE, MN
Confronta SRDX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
SRDX
Surmodics Inc
|
29.40 | 414.96M | 138.20M | 5.52M | 9.86M | 0.38 |
![]()
ABT
Abbott Laboratories
|
133.58 | 232.41B | 42.34B | 13.50B | 6.66B | 7.71 |
![]()
BSX
Boston Scientific Corp
|
102.09 | 155.73B | 17.55B | 2.03B | 2.72B | 1.37 |
![]()
SYK
Stryker Corp
|
383.89 | 146.23B | 23.22B | 2.86B | 3.58B | 7.40 |
![]()
MDT
Medtronic Plc
|
87.44 | 106.37B | 33.54B | 4.66B | 5.19B | 3.62 |
![]()
EW
Edwards Lifesciences Corp
|
77.52 | 45.88B | 5.54B | 4.18B | 623.10M | 7.00 |
Surmodics Inc Stock (SRDX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-03-07 | Aggiornamento | Lake Street | Hold → Buy |
2023-06-13 | Aggiornamento | Needham | Hold → Buy |
2023-02-13 | Downgrade | Needham | Buy → Hold |
2020-07-23 | Aggiornamento | Needham | Hold → Buy |
2019-12-11 | Downgrade | Needham | Buy → Hold |
2019-11-01 | Downgrade | Lake Street | Buy → Hold |
2019-08-01 | Reiterato | Needham | Buy |
2019-05-02 | Reiterato | Lake Street | Buy |
2019-05-02 | Reiterato | Needham | Buy |
2019-02-21 | Reiterato | Needham | Buy |
2018-05-16 | Reiterato | Needham | Buy |
2018-03-01 | Aggiornamento | Sidoti | Neutral → Buy |
2018-02-28 | Reiterato | Lake Street | Buy |
2018-02-28 | Iniziato | Needham | Buy |
2017-07-14 | Iniziato | Lake Street | Buy |
2016-11-21 | Downgrade | Barrington Research | Outperform → Mkt Perform |
2016-10-06 | Downgrade | Sidoti | Buy → Neutral |
2016-05-03 | Reiterato | Barrington Research | Outperform |
2015-08-06 | Reiterato | Barrington Research | Outperform |
2015-03-27 | Iniziato | Dougherty & Company | Buy |
2014-02-25 | Iniziato | Laidlaw | Buy |
2013-08-01 | Aggiornamento | Feltl & Co. | Buy → Strong Buy |
2012-11-12 | Reiterato | Barrington Research | Outperform |
Mostra tutto
Surmodics Inc Borsa (SRDX) Ultime notizie
Why Is SurModics (SRDX) Up 6% Since Last Earnings Report? - sharewise
Surmodics, Inc. (NASDAQ:SRDX) Shares Bought by Deutsche Bank AG - Defense World
Surmodics, Inc. (SRDX) Stock Analysis: Exploring a 47.46% Potential Upside in the Medical Devices Sector - DirectorsTalk Interviews
US FTC files amended complaint to block GTCR acquisition of Surmodics - MLex
Surmodics Shares Positive TRANSCEND Trial Results - Medical Product Outsourcing
Surmodics Reports First Quarter of Fiscal Year 2025 Financial Results - ADVFN
Equities Analysts Issue Forecasts for Surmodics Q2 Earnings - Defense World
Legal & General Group Plc Buys 880 Shares of Surmodics, Inc. (NASDAQ:SRDX) - Defense World
Zacks Research Weighs in on Surmodics FY2025 Earnings - Defense World
Are Options Traders Betting on a Big Move in Surmodics Stock? - Yahoo Finance
SRDX Stock Down Following Q2 Earnings Miss, Gross Margin Contracts - TradingView
SurModics: Fiscal Q2 Earnings Snapshot - New Haven Register
Surmodics Reports Q2 2025 Results Amid Acquisition Challenges - TipRanks
SurModics (SRDX) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Finance
SurModics stock touches 52-week low at $26.21 amid market shifts - Investing.com
Surmodics (SRDX) Projects Declining Revenue for Fiscal 2025 | SR - GuruFocus
Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance - BioSpace
Surmodics (SRDX) Projects Declining Revenue for Fiscal 2025 | SRDX Stock News - GuruFocus
Surmodics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
SurModics (SRDX) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Surmodics (SRDX) Reports Lower Than Expected Q2 Revenue Amid Ant - GuruFocus
Surmodics Reports Second Quarter of Fiscal Year 2025 Financial R - GuruFocus
SURMODICS INC SEC 10-Q Report - TradingView
Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance | SRDX Stock News - GuruFocus
Surmodics Reports Second Quarter Fiscal 2025 Financial Results - TradingView
A Look at Surmodics's Upcoming Earnings Report - Nasdaq
How To Trade (SRDX) - news.stocktradersdaily.com
Surmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30 - 01net
Surmodics to Report Second Quarter of Fiscal 2025 Financial Resu - GuruFocus
FTC Expands Lawsuit Against GTCR Over Surmodics Acquisition - MSN
Surmodics' SurVeil DCB Matches IN.PACT Admiral In Efficacy With Lower Drug Dose In Global Trial - Nasdaq
Surmodics (SRDX) Publishes Promising Clinical Trial Results for SurVeil DCB | SRDX Stock News - GuruFocus
Surmodics Announces Publication of TRANSCEND Trial, Highlighting - GuruFocus
Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated Balloon - Business Wire
Attorney General Ellison sues to block harmful private-equity acquisition of Minnesota medical-device coating company - Red Lake Nation News
Illinois, Minnesota join FTC challenge against $627M Surmodics buyout - MedTech Dive
Minnesota AG Ellison joins federal lawsuit to stop merger of companies that make medical device coatings - KIMT
Illinois joins FTC suit to block GTCR’s takeover of Surmodics - Crain's Chicago Business
AG Ellison Joins Suit to Block Surmodics Acquisition - Twin Cities Business
Corebridge Financial Inc. Lowers Stock Position in Surmodics, Inc. (NASDAQ:SRDX) - Defense World
(SRDX) Long Term Investment Analysis - news.stocktradersdaily.com
Surmodics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire
SRDX Stock Dips Despite the Launch of Pounce XL Thrombectomy System - Yahoo Finance
Surmodics launches Pounce XL for peripheral artery clot removal By Investing.com - Investing.com South Africa
Surmodics launches Pounce XL thrombectomy system - Yahoo Finance
Surmodics Inc Azioni (SRDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Surmodics Inc Azioni (SRDX) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
DANTZKER DAVID | Director |
Feb 13 '25 |
Option Exercise |
27.30 |
5,275 |
144,008 |
44,399 |
BEDOYA JOSE H | Director |
Feb 14 '25 |
Option Exercise |
27.30 |
5,275 |
144,008 |
34,232 |
KNIGHT SUSAN E | Director |
Jan 24 '25 |
Option Exercise |
27.30 |
7,358 |
200,873 |
42,506 |
Arens Timothy J. | Chief Financial Officer |
Nov 26 '24 |
Sale |
39.44 |
7,009 |
276,453 |
70,350 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):